ArticleAngewandte Chemie (International ed. in English)2026
Pseudotetraivprolides from Pseudomonas entomophila Provide Insights into the Biosynthesis of Detoxin/Rimosamide-Like Anti-Antibiotics.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Heterologous Production of Barnesin A, an NRPS-PKS Hybrid Containing a Rare Vinylogous Arginine Moiety.Chembiochem : a European journal of chemical biology · 2026Article
- Pseudotetraivprolides from Pseudomonas entomophila Provide Insights into the Biosynthesis of Detoxin/Rimosamide-Like Anti-Antibiotics.Angewandte Chemie (International ed. in English) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Novel variants of known natural product (NP) classes can provide valuable insights into their biosynthesis, mechanisms of action, and potential as drug leads across the entire class. Here, we describe a novel member of the widespread detoxine/rimosamide-like (DRL) natural products, named pseudotetraivprolide, produced by Pseudomonas strains. Pseudotetraivprolide exhibits the characteristic DRL-activity of protecting Bacillus cereus against the antibiotic blasticidin S. Through the generation of multiple deletion and complementation mutants, heterologous expression experiments, identification and structure elucidation of several derivatives, chemical synthesis of main derivatives, enzymatic characterization of individual biochemical steps, and detailed homology modelling of enzyme complexes, we elucidated key aspects of its biosynthesis. Our findings demonstrate that the primary metabolism-derived malonyl CoA:ACP transacylase (FabD) functions as a trans-AT in the biosynthesis pathway. Furthermore, we suggest an order for all late-stage modifications and assign a function for the three conserved hypothetical proteins PipDFG acting as last-step acetylation complex responsible for stabilization and activation of the final product.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.